Q. Q. Wu1, X. B. Zheng2, Y. X. Chen3, P. Yang3, J. Sun2, S. Du2, and Z. C. Zeng3; 1Fudan Univerisity Zhongshan Hospital(Xiamen), Xiamen, China, 2Zhongshan Hospital Fudan University, Shanghai, China, 3Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
Purpose/Objective(s): This study aimed to develop the combination of dose-volume features and clinical characteristics that can predict patient progression free survival in hepatocellular carcinoma (HCC) treated with stereotactic body radiotherapy (SBRT). Materials/
Methods: Ninety-nine HCC patients treated with SBRT during 2015-2022 were enrolled and divided into Progression and Non-progression Group. The dose-volume features were extracted from treatment plan system. Cox proportional hazards regression and least absolute shrinkage and selection operator analyses were performed to select relevant clinical parameters. The predictive performance of our model was evaluated by time-dependent receiver operating characteristic (ROC) curve and calibration curve analyses. Results: Three clinical features (complete response in 6 months, Age, Previous TACE treatment) and two dosimetric parameters (The relative volume of total liver treated with =5 Gy, Biological effective dose) were identified as the best progression free survival related predictors. Participants were divided into a high-risk group and a low-risk group based on the selected features. The areas under the ROC curve for our prognostic model were 0.79, 0.88, 0.87 for 1-, 2-, and 3- progression free survival, respectively. The calibration curve of the 5 independent PFS-related markers showed a good fit between nomogram-predicted PFS and actual PFS, suggesting that our model has good predictive value. Conclusion: This study demonstrated that a nomogram of combined dosimetric features and clinical characteristics can be conveniently used to assess individualized post-radiation prediction of PFS in HCC patients treated with SBRT.
